Krishna Institute of Medical Sciences Ltd

The committee approved the opening of the issue on 16 June 2026. The floor price of Rs 771.73 per equity share is at a discount of 0.83% to the scrip's previous closing price of Rs 778.15 on the BSE. The company may offer a discount of not more than 5% on the floor price for the issue. The issue price will be determined in consultation with the bookrunning lead managers appointed for the issue. The Finance & Investment Committee is scheduled to meet on 19 June 2026 to consider and approve the issue price, including any discount thereto, in accordance with SEBI regulations. Headquartered in Hyderabad, Krishna Institute of Medical Sciences (KIMS Hospitals) is one of the largest corporate healthcare groups in Telangana and Andhra Pradesh, providing multidisciplinary integrated healthcare services, with a focus on tertiary and quaternary healthcare at an affordable cost. The company's consolidated net profit declined 58.25% to Rs 42.50 crore despite a 34.85% increase in revenue to Rs 1,074.60 crore in Q4 FY26 over Q4 FY25. Powered by Capital Market - Live

Krishna Institute of Medical Sci. announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 9 July 2026.

Each warrant is convertible into one equity share within 18 months from the date of allotment. Of the total proposed issuance, 64.19 lakh warrants aggregating Rs 500 crore will be allotted to promoters Dr. Abhinay Bollineni and Mr. Advik Bollineni, while 12.84 lakh warrants aggregating Rs 100 crore will be allotted to promoter-group entity Bharas Ventures LLP. The proposal remains subject to shareholder approval and other regulatory clearances. The company has also scheduled an extra-ordinary general meeting (EGM) for 09 July 2026 to seek shareholder consent for the same. Assuming 100% conversion of warrants, shareholding of Dr. Abhinay Bollineni will rise to 0.84% from 0.06% currently, and that of Adwik Bollineni will climb to 0.80% from 0.01%. Bharas Ventures LLP will own 0.31% stake in the company post warrant conversion. Bharas Ventures is a limited liability partnership between the company's two promoters, viz., Dr. Bhaskara Rao Bollineni and Ms. Rajyasri Bollineni. Headquartered in Hyderabad, Krishna Institute of Medical Sciences (KIMS Hospitals) is one of the largest corporate healthcare groups in Telangana and Andhra Pradesh, providing multi-disciplinary integrated healthcare services, with a focus on tertiary and quaternary healthcare at affordable cost. The company's consolidated net profit declined 58.25% to Rs 42.50 crore despite a 34.85% increase in revenue to Rs 1,074.60 crore in Q4 FY26 over Q4 FY25. The scrip fell 2.88% to end at Rs 787.10 on the BSE on Friday. Powered by Capital Market - Live

The proposed fund raise may involve equity shares, fully convertible warrants, convertible or non-convertible securities, or a combination thereof through permissible modes, including a preferential issue on a private placement basis or any other approved route. Headquartered in Hyderabad, Krishna Institute of Medical Sciences (KIMS Hospitals) is one of the largest corporate healthcare groups in Telangana and Andhra Pradesh, providing multi-disciplinary integrated healthcare services, with a focus on tertiary and quaternary healthcare at affordable cost. On consolidated basis, the company's net profit declined 58.25% to Rs 42.5 crore in Q4 FY26 from with Rs 101.8 crore in Q4 FY25. Revenue from operations Revenue from operations increased 34.85% YoY to Rs 1,074.6 crore in Q4 FY26.Powered by Capital Market - Live

Krishna Institute of Medical Sci. will hold a meeting of the Board of Directors of the Company on 13 June 2026.

Krishna Institute of Medical Sci. announced that the 24th Annual General Meeting(AGM) of the company will be held on 27 August 2026.

Net profit of Krishna Institute of Medical Sciences declined 58.25% to Rs 42.50 crore in the quarter ended March 2026 as against Rs 101.80 crore during the previous quarter ended March 2025. Sales rose 34.85% to Rs 1074.60 crore in the quarter ended March 2026 as against Rs 796.90 crore during the previous quarter ended March 2025. For the full year,net profit declined 37.22% to Rs 241.40 crore in the year ended March 2026 as against Rs 384.50 crore during the previous year ended March 2025. Sales rose 28.65% to Rs 3904.60 crore in the year ended March 2026 as against Rs 3035.00 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1074.60796.90 35 3904.603035.00 29 OPM %19.2224.85 -20.5425.79 - PBDT150.70175.80 -14 628.30724.40 -13 PBT65.70123.20 -47 345.10547.10 -37 NP42.50101.80 -58 241.40384.50 -37 Powered by Capital Market - Live

The agreement covers 2 acres of land in Amravati. The proposed multi-speciality hospital will offer comprehensive tertiary and quaternary care across cardiology, oncology, neurosciences, gastroenterology, orthopaedics, mother & child care, critical care, organ transplant and other key specialties, addressing a long-standing need for advanced healthcare infrastructure in the region. Once operational, patients in Amaravati and surrounding districts of Andhra Pradesh will gain access to high-end clinical capabilities, reducing the need of travel to other metros for specialised care. Headquartered in Hyderabad, Krishna Institute of Medical Sciences (KIMS Hospitals) is one of the largest corporate healthcare groups in Telangana and Andhra Pradesh, providing multi-disciplinary integrated healthcare services, with a focus on tertiary and quaternary healthcare at affordable cost. The company's consolidated net profit declined 39.8% to Rs 53.40 crore despite of 29.2% increase in revenue from operations to Rs 997.70 crore in Q3 FY26 over Q3 FY25. The counter advanced 1.41% to end at Rs 717.55 on the BSE.Powered by Capital Market - Live

Krishna Institute of Medical Sci. will hold a meeting of the Board of Directors of the Company on 15 May 2026.

The board of Krishna Institute of Medical Sciences at its meeting held on 11 March 2026 has approved fund raising up to Rs 1,500 crore by way of QIP issue. Powered by Capital Market - Live